Literature DB >> 29119220

Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: Ready for prime time?

José-Artur Paiva1,2, Pierre-Emmanuel Charles3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29119220     DOI： 10.1007/s00134-017-4990-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  17 in total

1.  Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.

Authors:  David Ferreira; Frederic Grenouillet; Gilles Blasco; Emmanuel Samain; Thierry Hénon; Alain Dussaucy; Laurence Millon; Mariette Mercier; Sebastien Pili-Floury
Journal:  Intensive Care Med       Date:  2015-04-18       Impact factor: 17.440

2.  Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.

Authors:  Sébastien Bailly; Olivier Leroy; Philippe Montravers; Jean-Michel Constantin; Hervé Dupont; Didier Guillemot; Olivier Lortholary; Jean-Paul Mira; Pierre-François Perrigault; Jean-Pierre Gangneux; Elie Azoulay; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2015-09-14       Impact factor: 17.440

3.  Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.

Authors:  Anahita Rouzé; Séverine Loridant; Julien Poissy; Benoit Dervaux; Boualem Sendid; Marjorie Cornu; Saad Nseir
Journal:  Intensive Care Med       Date:  2017-09-22       Impact factor: 17.440

Review 4.  Intensive care medicine research agenda on invasive fungal infection in critically ill patients.

Authors:  Matteo Bassetti; Jose Garnacho-Montero; Thierry Calandra; Bartjan Kullberg; George Dimopoulos; Elie Azoulay; Arunaloke Chakrabarti; Daniel Kett; Cristobal Leon; Luis Ostrosky-Zeichner; Maurizio Sanguinetti; Jean-Francois Timsit; Malcom D Richardson; Andrew Shorr; Oliver A Cornely
Journal:  Intensive Care Med       Date:  2017-03-02       Impact factor: 17.440

5.  MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.

Authors:  Luis Ostrosky-Zeichner; Shmuel Shoham; Jose Vazquez; Annette Reboli; Robert Betts; Michelle A Barron; Mindy Schuster; Marc A Judson; Sanjay G Revankar; Juan Pablo Caeiro; Julie E Mangino; David Mushatt; Roger Bedimo; Alison Freifeld; Minh Hong Nguyen; Carol A Kauffman; William E Dismukes; Andrew O Westfall; Jeanna Beth Deerman; Craig Wood; Jack D Sobel; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2014-02-18       Impact factor: 9.079

6.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

7.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

8.  Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report.

Authors:  Pierre Emmanuel Charles; Emmanuel Kus; Serge Aho; Sébastien Prin; Jean-Marc Doise; Nils-Olivier Olsson; Bernard Blettery; Jean-Pierre Quenot
Journal:  BMC Infect Dis       Date:  2009-04-22       Impact factor: 3.090

9.  Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014.

Authors:  Snigdha Vallabhaneni; Angela A Cleveland; Monica M Farley; Lee H Harrison; William Schaffner; Zintar G Beldavs; Gordana Derado; Cau D Pham; Shawn R Lockhart; Rachel M Smith
Journal:  Open Forum Infect Dis       Date:  2015-12-14       Impact factor: 3.835

10.  Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study.

Authors:  Olivier Leroy; Sébastien Bailly; Jean-Pierre Gangneux; Jean-Paul Mira; Patrick Devos; Hervé Dupont; Philippe Montravers; Pierre-François Perrigault; Jean-Michel Constantin; Didier Guillemot; Elie Azoulay; Olivier Lortholary; Caroline Bensoussan; Jean-François Timsit
Journal:  Ann Intensive Care       Date:  2016-01-08       Impact factor: 6.925
View more
  1 in total

1.  ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.

Authors:  Ignacio Martin-Loeches; Massimo Antonelli; Manuel Cuenca-Estrella; George Dimopoulos; Sharon Einav; Jan J De Waele; Jose Garnacho-Montero; Souha S Kanj; Flavia R Machado; Philippe Montravers; Yasser Sakr; Maurizio Sanguinetti; Jean-Francois Timsit; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2019-03-25       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.